sutenttm Search Results


sutenttm  (Pfizer Inc)
90
Pfizer Inc sutenttm
a. Comparison of biopsy and nephrectomy for all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was present, either because the target's regions were filtered due to low average counts, or because no methylation cores were present for the target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential region according to P -value. VHL is the only target that has FDR under the 0.1 significance level ( i.e. 0.077). The P -value is 0.00086 and the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen in patients with a good vs poor response to <t>sunitinib</t> ( P = 0.896, Student's t -test).
Sutenttm, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sutenttm/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
sutenttm - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
sut sutenttm  (Pfizer Inc)
90
Pfizer Inc sut sutenttm
a. Comparison of biopsy and nephrectomy for all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was present, either because the target's regions were filtered due to low average counts, or because no methylation cores were present for the target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential region according to P -value. VHL is the only target that has FDR under the 0.1 significance level ( i.e. 0.077). The P -value is 0.00086 and the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen in patients with a good vs poor response to <t>sunitinib</t> ( P = 0.896, Student's t -test).
Sut Sutenttm, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sut sutenttm/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
sut sutenttm - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
n o n h sunitinib (sutenttm)  (Pfizer Inc)
90
Pfizer Inc n o n h sunitinib (sutenttm)
a. Comparison of biopsy and nephrectomy for all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was present, either because the target's regions were filtered due to low average counts, or because no methylation cores were present for the target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential region according to P -value. VHL is the only target that has FDR under the 0.1 significance level ( i.e. 0.077). The P -value is 0.00086 and the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen in patients with a good vs poor response to <t>sunitinib</t> ( P = 0.896, Student's t -test).
N O N H Sunitinib (Sutenttm), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n o n h sunitinib (sutenttm)/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
n o n h sunitinib (sutenttm) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
sutenttm capsules  (Pfizer Inc)
90
Pfizer Inc sutenttm capsules
a. Comparison of biopsy and nephrectomy for all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was present, either because the target's regions were filtered due to low average counts, or because no methylation cores were present for the target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential region according to P -value. VHL is the only target that has FDR under the 0.1 significance level ( i.e. 0.077). The P -value is 0.00086 and the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen in patients with a good vs poor response to <t>sunitinib</t> ( P = 0.896, Student's t -test).
Sutenttm Capsules, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sutenttm capsules/product/Pfizer Inc
Average 90 stars, based on 1 article reviews
sutenttm capsules - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


a. Comparison of biopsy and nephrectomy for all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was present, either because the target's regions were filtered due to low average counts, or because no methylation cores were present for the target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential region according to P -value. VHL is the only target that has FDR under the 0.1 significance level ( i.e. 0.077). The P -value is 0.00086 and the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen in patients with a good vs poor response to sunitinib ( P = 0.896, Student's t -test).

Journal: Oncotarget

Article Title: Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer

doi: 10.18632/oncotarget.8308

Figure Lengend Snippet: a. Comparison of biopsy and nephrectomy for all patients. Target label displayed in each subplot. False discovery rate (FDR) is provided in parenthesis. NA = no methylation core was present, either because the target's regions were filtered due to low average counts, or because no methylation cores were present for the target in the methylome map. If there was more than one region for a certain target, the Figure only shows the most significantly differential region according to P -value. VHL is the only target that has FDR under the 0.1 significance level ( i.e. 0.077). The P -value is 0.00086 and the logFC -0.8734. The latter implies that the post-treatment samples are more methylated in average than the pre-treatment ones. This is only the case for the methylation core in the VHL promoter region 7896829 located from nt 10183068 to nt 10183220 on chromosome 3; other VHL regions are not found to be differentially methylated under this significance level. b. Per patient methylation of VHL at region 7896829. For all samples methylation was greater in the post-treatment nephrectomy samples than the pre-treatment biopsy. Results divided into patients who had a good or poor response to treatment, there was no significant difference in the VHL hypermethylation seen in patients with a good vs poor response to sunitinib ( P = 0.896, Student's t -test).

Article Snippet: Primary tumor tissue (the “sunitinib set”) was collected and snap frozen from mccRCC patients treated with three cycles of pre-surgical sunitinib (SutentTM, Pfizer, Sandwich, UK), for 18 weeks, as a translational endpoint of a previously reported prospective clinical trial (SuMR; NCT01024205) [ ].

Techniques: Comparison, Methylation